Corrigendum to “PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens” (Colloids and Surfaces B: Biointerfaces (2015) 132 (62–70), (S0927776515002696) (10.1016/j.colsurfb.2015.04.050));PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens

Colloids and Surfaces B: Biointerfaces

Volumn 132, Issue , 2015, Pages 62-70

  Marslin, Gregory ^a   Revina, Ann Mary ^a,b   Khandelwal, Vinoth Kumar Megraj ^c   Balakumar, Krishnamoorthy ^d   Sheeba, Caroline J ^a,b,e   Franklin, Gregory ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

^d PSG COLLEGE OF PHARMACY   (India)

^e UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Antibacterial; Antibiotic resistance; Bacterial uptake; MPEG PLGA diblock Co polymer; Nanoparticles; Ofloxacin

Indexed keywords

ANTIBIOTICS; BACTERIOLOGY; ESCHERICHIA COLI; NANOPARTICLES; POLYETHYLENE GLYCOLS; SALMONELLA;

ANTIBACTERIAL; ANTIBIOTIC RESISTANCE; BACTERIAL UPTAKE; DI-BLOCK COPOLYMERS; OFLOXACIN;

DRUG DELIVERY;

COPOLYMER; MACROGOL; METHOXY POLY(ETHYLENE GLYCOL) B POLY(LACTIC CO GLYCOLIC ACID); OFLOXACIN; POLYGLACTIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; MACROGOL DERIVATIVE; NANOPARTICLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERIAL TRANSLOCATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; ESCHERICHIA COLI; GROWTH INHIBITION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST;

BACILLUS SUBTILIS; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACILLUS SUBTILIS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; OFLOXACIN; POLYETHYLENE GLYCOLS;

EID: 84929587402     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2019.01.063     Document Type: Erratum

References (37)

1. Shaoo A.S.S., Nanda R., Phani A.R., Nayak P.L. Synthesis of chitosan-polycaprolactone blend for control delivery of ofloxacin drug. Carbohydr. Polym. 2010, 7:106-113.
2. Monk J.P., Campoli-Richards D.M. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987, 33:346-391.
3. Djurdjevic P.T., Jelikic-Stankov M. Study of solution equilibria between aluminum(III) ion and ofloxacin. J. Pharm. Biomed. Anal. 1999, 19:501-510.
4. Mizuki Y., Fujiwara I., Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J. Antimicrob. Chemother. 1996, 37(Suppl. A):41-55.
5. Furneri P.M., Fresta M., Puglisi G., Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob. Agents Chemother. 2000, 44:2458-2464.
6. Baskin H., Dogan Y., Bahar I.H., Yulug N. Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli. Int. J. Antimicrob. Agents 2002, 19:79-82.
7. Namasivayam S.K.R., Samrat K., Ganesh S. Preparation of chitosan stabilized ofloxacin-gold nano conjugate for the improved anti-bacterial activity against human pathogenic bacteria. Innovare J. Med. Sci. 2013, 1:7-11.
8. Dalhoff A. Resistance surveillance studies: a multifaceted problem - the fluoroquinolone example. Infection 2012, 40:239-262.
9. Drlica K., Hiasa H., Kerns R., Malik M., Mustaev A., Zhao X. Quinolones: action and resistance updated. Curr. Top. Med. Chem. 2009, 9:981-998.
10. Li X.Z., Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009, 69:1555-1623.
11. Beceiro A., Tomas M., Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin. Microbiol. Rev. 2013, 26:185-230.
12. Reilman E., Mars R.A., van Dijl J.M., Denham E.L. The multidrug ABC transporter BmrC/BmrD of Bacillus subtilis is regulated via a ribosome-mediated transcriptional attenuation mechanism. Nucleic Acids Res. 2015, 42:11393-11407.
13. Sheeba C.J., Marslin G., Revina A.M., Franklin G. Signaling pathways influencing tumor microenvironment and their exploitation for targeted drug delivery. Nanotechnol. Rev. 2014, 3(2):123-151.
14. Abed N., Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int. J. Antimicrob. Agents 2014, 43:485-496.
15. Marslin G., Sheeba C.J., Kalaichelvan V.K., Manavalan R., Reddy P.N., Franklin G. Poly(d,l-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in rat. J. Biomed. Nanotechnol. 2009, 5:464-471.
16. Elmarzugi N., Adali T., Bentaleb A., Keleb E., Mohamed A., Hamza A. Spectroscopic characterization of PEG-DNA biocomplexes by FTIR. J. Appl. Pharm. Sci. 2014, 4(08):6-10.
17. Froehlich E., Mandeville J.S., Weinert C.M., Kreplak L., Tajmir-Riahi H.A. Bundling and aggregation of DNA by cationic dendrimers. Biomacromolecules 2011, 12:511-517.
18. Johnson B.M., Charman W.N., Porter C.J. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E da-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm. Sci. 2002, 4:E40.
19. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 2008, 25:500-511.
20. Liu P., Yu H., Sun Y., Zhu M., Duan Y. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 2012, 33:4403-4412.
21. Mondal S., Roy P., Das S., Halder A., Mukherjee A., Bera T. In vitro susceptibilities of wild and drug resistant leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacy. PLOS ONE 2013, 8:e81492.
22. Hua S., Yang H., Wang W., Wang A. Controlled release of ofloxacin from chitosan-montmorillonite hydrogel. Appl. Clay Sci. 2010, 50:112-117.
23. Abazinge M., Jackson T., Yang Q., Owusu-Ababio G. Comparison of in vitro and in vivo release characteristics of sustained release ofloxacin microspheres. Drug Deliv. 2000, 7:77-81.
24. Paulsen I.T., Chen J., Nelson K.E., Saier M.H. Comparative genomics of microbial drug efflux systems. J. Mol. Microbiol. Biotechnol. 2001, 3:145-150.
25. Aldred K.J., Kerns R.J., Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014, 53:1565-1574.
26. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip. Perspect. Infect. Dis. 2012, 2012:976273.
27. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74:417-433.
28. Chung C.T., Niemela S.L., Miller R.H. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:2172-2175.
29. Romero V.L., Manzo R.H., Alovero F.L. Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa. J. Chemother. 2010, 22:328-334.
30. Romero V.L., Pons P., Bocco J.L., Manzo R.H., Alovero F.L. Eudragit E100(R) potentiates the bactericidal action of ofloxacin against fluoroquinolone-resistant Pseudomonas aeruginosa. FEMS Microbiol. Lett. 2012, 334:102-110.
31. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 325:1089-1093.
32. Ahmed M., Lyass L., Markham P.N., Taylor S.S., Vazquez-Laslop N., Neyfakh A.A. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J. Bacteriol. 1995, 177:3904-3910.
33. Kumar M.M.S., Varela F.M. Modulation of bacterial multidrug resistance efflux pumps of the major facilitator superfamily. Int. J. Bacteriol. 2013, 1-15.
34. Van Bambeke F., Glupczynski Y., Plesiat P., Pechere J.C., Tulkens P.M. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J. Antimicrob. Chemother. 2003, 51:1055-1065.
35. Van Bambeke F., Michot J.M., Tulkens P.M. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J. Antimicrob. Chemother. 2003, 51:1067-1077.
36. Muppidi K., Wang J., Betageri G., Pumerantz A.S. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob. Agents Chemother. 2011, 55:4537-4542.
37. Xie S., Tao Y., Pan Y., Qu W., Cheng G., Huang L., Chen D., Wang X., Liu Z., Yuan Z. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J. Control. Release 2014, 187:101-117.